



On June 23th, Sinopharm CNBG commencement ceremony for the phase III clinical trial of inactivated COVID-19 Vaccine of the United Arab Emirates was held in Beijing, Wuhan, Abu Dhabi, UAE, simultaneously by video conference. The minister of Health of the United Arab Emirates gave a message to Sinopharm CNBG issued a clinical trial approval document.





▲ China and UAE simultaneously issued clinical trial approval documents

China and the UAE signed relevant clinical cooperation agreement at the ceremony, marking the official launch of the world's first international clinical trial of the inactivated COVID-19 vaccine (Phase III). This is the implementation of President Xi Jinping, who delivered a speech at the world health assembly on "China's COVID-19 vaccine is completed and will be used as a global public product after the research and development, making China's contribution to the realization of vaccine accessibility and affordability in developing countries." The phase achievement of the spirit of the speech is the first international Phased III clinical study of a Chinese-original vaccine, and the first overseas clinical trial of China's COVID-19 vaccine, which is important for promoting the early use of the vaccine, a key step has been taken to benefit of humanity.



▲ Yang Xiaoming, chairman of CNBG (right), Li Can, general manager of Sinopharm International (left) signed relevant clinical cooperation agreement with the United Arab Emirates on the spot.

The meeting was attended by  
Chen Zhu, the president of the Chinese Red Cross,  
Hao Peng, the director of SASAC of the State Council,  
Ren Hongbin, deputy director of SASAC of the State Council,  
Xiao Juhua, vice governor of Hubei Province,  
Liu Ziqing, vice mayor of Wuhan,  
Ni Jian, China's ambassador to the United Arab Emirates,  
Gao Fu, director of the China Center for Disease Control,  
Liu Jingzhen, chairman of Sinopharm Group,  
Abdul Rahman Mohamed Al Oves, minister of health of UAE,  
Hamdan Musharra Al Muzuri, head of Red Crescent, UAE  
Ali Zahiri, UAE Ambassador to China,  
Xiao Peng, CEO of UAE G42 Group etc.



▲ Venue in Beijing





▲ Venue in Abu Dhabi, UAE



▲ Venue in Wuhan

In his speech, Hao Peng pointed out that the cooperation between China and the United Arab Emirates in science and technology enterprises marks new and important progress in international epidemic prevention cooperation, which will certainly promote the early use of vaccines for the

benefit of the people of all countries. It is hoped that all parties involved in clinical research cooperation will uphold the concept of the human destiny community, support each other and cooperate closely to realize the safety, effectiveness, and accessibility of vaccines, and contribute wisdom and strength to the early victory of the epidemic.



▲ Hao Peng, the director of SASAC of the State Council

In his speech, Ni Jian, who is China's ambassador to the United Arab Emirates, said that the international clinical trial of inactivated COVID-19 vaccine, which was conducted by China Sinopharm CNBG, in the United Arab Emirates, was not only a useful attempt for international cooperation against the epidemic. It is also a vivid embodiment of China-Arab comprehensive strategic partnership. Since the outbreak of the COVID-19 epidemic, China has taken the most comprehensive, strictest and thorough measures to prevent and control the epidemic, resolutely curb the momentum of the spread of the epidemic, share the experience of prevention and control and treatment with the United Arab Emirates and other countries in the world. Inactivated COVID-19 vaccine of China Sinopharm CNBG, has been approved to start the clinical experiment and is one of the fastest vaccines in the world to enter the human clinical experiment, which has brought the hope and the dawn for the human to defeat the coronavirus epidemic situation.



▲ Ni Jian, China's Ambassador to the United Arab Emirates



▲ Abdul Rahman Mohammed Al Ovis,  
Minister of Health of the United Arab Emirates Addressing

The G42 company is Abu Dhabi-based artificial intelligence (AI) and cloud computing companies, providing leading artificial intelligence solutions for key industries in the UAE's national ecosystem. And it has Artemis, which is the world's top26th supercomputer. As the technical

response unit responsible for the "UAE National Genome Project" and the COVID-19 epidemic, G42 will also cooperate with Sinopharm CNBG on local production and other issues to benefit the people of the UAE and the Middle East.

On April 12th, the inactivated COVID-19 vaccine developed by China Wuhan Institute of Biological Products Co. Ltd is the first phase I / II clinical trial in the world. On April 27th, The inactivated COVID-19 vaccine developed by China Beijing Institute of Biological products has also entered phase I / II clinical trials. Phase I / II clinical studies of the two vaccines included 2240 people. The results of phase I/II clinical trial of Wuhan Institute of Biological Products on June 16 showed good safety after vaccination and no serious adverse reactions occurred. After different procedures and doses, vaccine group vaccinators produced high titer antibodies. After two doses, the positive conversion rate of neutralizing antibodies was 100%. The results of phase I / II clinical trials at the Beijing Institute of Biological products will be unveiled on June 28th. Previously, the 180 volunteers, including the party and government leaders of the four-level enterprises affiliated to the Sino Pharm Group, took the lead in inoculating the inactivated vaccine of the COVID-19, the volunteers' human forecasters showed, the subjects' antibodies have reached the level of resistance to the coronavirus, 100% protection; Recently, more than 1000 Sino Pharm Group cadres and employees voluntarily inoculated. It also shows that vaccines are safe and effective. The incidence and extent of adverse reactions are much lower than those of all kinds of vaccines that have been listed.

While promoting vaccine research and development, Sinopharm CNBG promotes the construction of high-grade biosafety production facilities at wartime speed. On April 15th, the Beijing Institute of Biological Products established the first and only high-grade biosafety production facility in China. After being put into use, the production capacity of the COVID-19 vaccine will reach 120 million doses per year. And the annual production capacity can be up to 100 million doses per year after the construction of high-grade biosafety production facilities of Wuhan Institute of Biological Products is completed.





▲ The largest production workshop of inactivated COVID-19 vaccine in the world,  
which belong to CNBG and is located in Beijing

Clinical studies are usually divided into three phases. Phase I mainly evaluates safety. Phase II mainly evaluates the safety and immunogenicity of the vaccine, and explore the immune procedure. Phase III mainly evaluates the safety and efficacy of the vaccine in a larger population.

In view of the effective control of the domestic epidemic situation and the lack of stage III clinical trial conditions, Chinese medicine group Chinese biology has actively promoted overseas cooperation in phase III clinical trials while doing a solid job in domestic phase I / II clinical trials. Cooperation framework agreements have been signed with relevant institutions in many countries. Liu Jingzhen, chairman of the Chinese Medicines Group, said the next step would be to do a good job in the UAE international clinical (phase III) trial in accordance with the clinical research program. Speed up international clinical cooperation with other countries and regions. Strengthen close communication with the World Health Organization, implement the WHO Solidarity Plan, prepare emergency pre-certification of the new crown vaccine, ensure that the vaccine completes clinical trials, strive to be listed at home and abroad as soon as possible, and ensure the accessibility and affordability of the vaccine.





▲ Liu Jingzhen, chairman of Sino Pharm Group

Sinopharm CNBG carries the history of the Chinese biological products industry for 100 years. It is the earliest enterprise in China to produce vaccinia, cholera, meningitis, and DPT vaccine. It is the main force and vanguard in eliminating smallpox, eliminating polio, controlling measles and hepatitis B, and is the founder of the Chinese biopharmaceutical industry. Sinopharm Group has a rich product line, covering six major biological products including human vaccines, blood products, medical beauty, animal health care, antibody drugs and medical diagnosis. The annual production capacity of the vaccine business alone exceeds 700 million doses and provides more than 80% of the immunization program vaccine for our country, is one of the top 5 vaccine suppliers in the world.

In the battle of epidemic prevention and control, the six major biological products research institutes of Sinopharm CNBG, which is located in Beijing, Wuhan, Chengdu, Lanzhou, Shanghai and Changchun, China Institute of Biotechnology and Tuantan Biological, took the lead in developing the coronavirus nucleic acid molecular detection reagent, a "searchlight" for accurate clinical diagnosis, the first to put forward the recovery phase plasma therapy, the "ballast stone globulin" for the treatment of severe patients, the first to develop the "golden key" for the treatment of the new crown pneumonia, and the first to develop the world's first new crown inactivated vaccine, the "killer mace ". It has made outstanding contributions to the prevention and control of the epidemic situation.